Driver mutations in melanoma: lessons learned from bench-to-bedside studies
about
Animal Models of Uveal Melanoma: Methods, Applicability, and LimitationsPhytochemicals for the Management of MelanomaA clinicopathological review of 33 patients with vulvar melanoma identifies c-KIT as a prognostic markerGermline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosisTERT Polymorphism rs2736100-C Is Associated with EGFR Mutation-Positive Non-Small Cell Lung CancerIdentifying core gene modules in glioblastoma based on multilayer factor-mediated dysfunctional regulatory networks through integrating multi-dimensional genomic data.Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma.Melanoma genotypes and phenotypes get personal.Ras and Rac1, frequently mutated in melanomas, are activated by superoxide anion, modulate Dnmt1 level and are causally related to melanocyte malignant transformation.Melanoma Expressed-CD70 Is Regulated by RhoA and MAPK Pathways without Affecting Vemurafenib Treatment Activity.Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma.The potential role of sunitinib targeting melanomas.miRNAs in melanoma: a defined role in tumor progression and metastasis.Intravitreally Injected HCmel12 Melanoma Cells Serve as a Mouse Model of Tumor Biology of Intraocular Melanoma.Regulatory properties of statins and rho gtpases prenylation inhibitiors to stimulate melanoma immunogenicity and promote anti-melanoma immune response.Matrine activates PTEN to induce growth inhibition and apoptosis in V600EBRAF harboring melanoma cells.Interaction of molecular alterations with immune response in melanoma.SUMO, PTEN and Tumor SuppressionAnalysis of KIT mutations and c-KIT expression in Chinese Uyghur and Han patients with melanoma.Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma.New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging.Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker.Molecular pathology of cutaneous melanoma
P2860
Q26745595-0E3FC564-011E-40B4-809C-958E3187D3DDQ26766708-89B93144-B7C8-4471-9B1C-96AAA566736EQ26991675-1EFDFD74-3AA2-44D8-B4DC-D4E5EC1A34FDQ28080034-1307A2B2-69E3-4AA2-9067-481788ED5C44Q28393844-AE1D2635-29D9-4F14-A738-DCF6944CD47BQ30887798-1F01BD40-8556-4F4D-B7D5-1A2677E5F651Q34576062-4080E3A6-876D-4F4C-9D12-120B20AEDF28Q34788817-4ECEB335-757E-46E0-875C-5F081FF2778BQ35072584-417DB6F0-39BD-4C87-A3C5-DF39B98E7EB5Q35909427-87D9B648-6CBA-424A-83B0-F90ECEBCCDFEQ37152975-7890CC31-67B4-488B-9C2E-CD6FDF6A80D9Q38139560-72689F97-D9A7-4250-BD11-D32ACF29E6F5Q38617229-DA9F3086-C005-49A4-BE68-DCE1AE1E297DQ38912348-10F2C912-EF84-4405-B1BC-0CFA4DBB9CC5Q38951511-0B3E074D-6111-4BB9-96E6-FB17B9BA4386Q39115959-F214D095-8532-4283-8A3A-8BE80609C2BAQ39329609-1EA852E1-18B6-4A89-B696-6B2DBA3942E9Q41867085-4F095E03-94B3-4FEB-A942-D89448536516Q44037924-EBC81070-0242-4583-8046-17FA1FE023B7Q47134263-26C912EB-CE3C-4EE6-A947-9B145B87C258Q48588744-8CF17C73-7B29-4AE1-89CD-49DC766342D5Q54372069-5B26D9CD-E813-4959-AC90-41A709C87AFAQ56428911-EEB80C64-9FD8-4128-98D2-C8D4A6A359AF
P2860
Driver mutations in melanoma: lessons learned from bench-to-bedside studies
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Driver mutations in melanoma: lessons learned from bench-to-bedside studies
@ast
Driver mutations in melanoma: lessons learned from bench-to-bedside studies
@en
Driver mutations in melanoma: lessons learned from bench-to-bedside studies
@nl
type
label
Driver mutations in melanoma: lessons learned from bench-to-bedside studies
@ast
Driver mutations in melanoma: lessons learned from bench-to-bedside studies
@en
Driver mutations in melanoma: lessons learned from bench-to-bedside studies
@nl
prefLabel
Driver mutations in melanoma: lessons learned from bench-to-bedside studies
@ast
Driver mutations in melanoma: lessons learned from bench-to-bedside studies
@en
Driver mutations in melanoma: lessons learned from bench-to-bedside studies
@nl
P2860
P1476
Driver mutations in melanoma: lessons learned from bench-to-bedside studies
@en
P2093
Harriet M Kluger
Janice M Mehnert
P2860
P2888
P304
P356
10.1007/S11912-012-0249-5
P577
2012-10-01T00:00:00Z
P6179
1051894542